Impact of Trump’s drug tariff on global healthcare

Ahron Young examines Trump’s proposed drug tariff and its impact on U.S. manufacturing and global healthcare costs

US President Donald Trump has unveiled plans to impose a 100% tariff on imported generic medicines from August 2028, saying the move will encourage pharmaceutical companies to bring manufacturing back to the United States.

The proposal is aimed at reducing America’s reliance on overseas drug production, particularly from countries including India and China, while strengthening domestic supply chains.

The Trump administration argues the policy will improve national security and create more manufacturing jobs.

However, the announcement has sparked concerns across the healthcare sector, with critics warning the tariffs could increase medicine prices, disrupt supply chains and limit access to affordable generic drugs.

Generic medicines account for the majority of prescriptions filled in the United States because they provide lower cost alternatives to branded treatments.

If import costs rise, healthcare providers and patients could ultimately face higher prices.

The proposal also puts pressure on multinational pharmaceutical companies that rely on overseas manufacturing.

Businesses will have until 2028 to decide whether to relocate production to the United States or absorb the additional costs.

Supporters believe the tariffs could strengthen America’s pharmaceutical industry over the long term, while opponents argue that rebuilding manufacturing capacity will take years and require more than tariffs alone.

Ticker News spoke with Politico’s Ari Hawkins about the economic, political and healthcare implications of the proposal, examining who stands to benefit, which companies face the biggest challenges and whether tariffs are the right solution to secure America’s medicine supply.

Subscribe to never miss an episode of Ticker – https://www.youtube.com/@weareticker